cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.25934/00007406
title: A Phase 3 Double-blind Study to Evaluate the Efficacy and Safety of Dexlansoprazole (30 mg QD) Compared to Placebo on Heartburn Relief in Subjects With Symptomatic Nonerosive Gastroesophageal Reflux Disease (GERD)

description: The purpose of this study is to determine the efficacy and safety of dexlansoprazole compared to placebo in relief of daytime and nighttime heartburn over 4 weeks in Chinese participants with symptomatic non-erosive Gastroesophageal Reflux Disease (GERD).
DOI: 10.25934/00007407
title: A Phase 1, Randomized, Open-Label, Single-Center, Single-Dose, Two-Period Two-Part Crossover Study in Healthy Subjects to Compare the Bioavailability of Dexlansoprazole From Dexlansoprazole Delayed-Release Capsules 30 mg and 60 mg Manufactured by Takeda GmbH Plant Oranienburg Relative to Dexlansoprazole Delayed-Release Capsules 30 mg and 60 mg Manufactured by Takeda Pharmaceutical Company Limited Osaka Plant

description: The purpose of this study is to assess the bioavailability of dexlansoprazole from a 30 milligram (mg) or 60 mg delayed-release capsule manufactured at Takeda GmbH Plant Oranienburg, Germany (TOB) relative to that of dexlansoprazole from a 30 mg or 60 mg capsule manufactured at Takeda Pharmaceutical Company Ltd. (Osaka, Japan) (TPC).
DOI: 10.25934/00007235
title: An Open-Label, Single-center, Parallel, Phase 1 Study to Determine the Pharmacokinetics of Single- and Multiple- Oral Doses of TAK-438 10 mg and 20 mg in Healthy Adult Chinese Subjects

description: The purpose of this study is to determine the pharmacokinetics (PK) of TAK-438 in healthy adult Chinese participants after both single and multiple dose administration.
DOI: 10.25934/00007408
title: A Phase 1, Randomized, Open-Label, Single-Center, Single-Dose, Two-Period, Two-Part Crossover Study in Healthy Subjects to Compare the Bioavailability of Dexlansoprazole From Dexlansoprazole Delayed-Release Capsules 30 mg and 60 mg Manufactured by Takeda GmbH Plant Oranienburg Relative to Dexlansoprazole Delayed-Release Capsules 30 mg and 60 mg Manufactured by Takeda Pharmaceutical Company Limited Osaka Plant Following a High-Fat Meal

description: The purpose of this study is to assess the BA of 30 or 60 milligram (mg) dexlansoprazole capsule manufactured at TOB (Takeda GmbH Plant Oranienburg) to the corresponding 30 or 60 mg dexlansoprazole manufactured at TPC (Takeda Pharmaceutical Company Ltd.).
DOI: 10.25934/00007236
title: A Phase 1, Double-Blind, Parallel Group Study to Evaluate the Safety and Pharmacokinetics of Quadruple Therapy (Bismuth, Clarithromycin, and Amoxicillin) With TAK-438 Versus Quadruple Therapy With Lansoprazole

description: To evaluate the safety, tolerability, and pharmacokinetics (PK) of quadruple therapy with bismuth, clarithromycin, amoxicillin, and TAK-438 versus quadruple therapy with bismuth, clarithromycin, amoxicillin, and lansoprazole.
DOI: 10.15468/dl.m7ex44
title: Occurrence Download

description: A dataset containing 19979 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Pittosporum tobira",
 "Country is Spain",
 "HasCoordinate is true"
 ]
}

 The dataset includes 19979 records from 44 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0037638-250920141307145/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.25934/00007237
title: A Randomized, Double-Blind, Double-Dummy Phase 3 Study to Evaluate the Efficacy and Safety of Oral Once-Daily Administration of TAK-438 20 mg Compared to Lansoprazole 30 mg in the Treatment of Subjects With Erosive Esophagitis

description: The purpose of the study is to demonstrate the efficacy of vonoprazan (TAK-438) versus lansoprazole in the treatment of erosive esophagitis classified as Los Angeles (LA) classification grades A to D at Week 8.
DOI: 10.25934/00007238
title: A Randomized Double-Blind, Double-Dummy, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-438 20 mg Compared to Lansoprazole 30 mg Once- or Twice-Daily in the Treatment of Endoscopically Confirmed Duodenal Ulcer Subjects With or Without Helicobacter Pylori Infection

description: The purpose of this study is to demonstrate the non-inferior efficacy of TAK-438 versus lansoprazole in the treatment of participants with duodenal ulcer.
DOI: 10.25934/00007239
title: A Randomized, Double-Blind, Double-Dummy, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of Oral Once-Daily Administration of TAK-438 10 or 20 mg Compared to Lansoprazole 15 mg in the Maintenance Treatment of Subjects With Endoscopic Healing of Erosive Esophagitis

description: This is a comparative study of vonoprazan (TAK-438) (10 mg or 20 mg) in participants in whom endoscopic healing of erosive esophagitis has been confirmed with vonoprazan or adequate treatment with a proton pump inhibitor (PPI), to demonstrate the non-inferiority of vonoprazan to lansoprazole in their maintenance treatment (6 months or 24 weeks) as well as to determine the clinically recommended dose for vonoprazan for maintenance therapy in erosive esophagitis.
DOI: 10.25934/00007240
title: A Phase 1, Randomized, Open-Label, Crossover Study to Evaluate the Bioequivalence of Single Oral Dose of TAK-438ASA Tablet and Single Oral Dose of TAK-438 Tablet Plus Aspirin Enteric-Coated Tablet (Study 1) and the Food Effect of Single Oral Dose of TAK-438ASA Tablet (Study 2) in Healthy Adult Male Subjects

description: The purposes of this study are to evaluate BE between a single-dose of TAK-438ASA tablet versus a single-dose combination of TAK-438 tablet 10 milligram (mg) and aspirin enteric-coated tablet 100 mg in Japanese healthy adult men (Study 1), and to evaluate the effects of food on the pharmacokinetics of TAK-438ASA tablet in Japanese healthy adult men (Study 2).
DOI: 10.25934/pr00008261
title: A Randomized, Open-Label and Double-Blind, Placebo-Controlled, Single- and Multiple-Dose, Phase 1 Study of the Pharmacokinetics of TAK-491 40 mg and 80 mg in Healthy Chinese Subjects

description: The purpose of this study is to assess the pharmacokinetics and safety of single- and multiple-dose of TAK-491 in healthy Chinese participants.
DOI: 10.25934/pr00008262
title: A Phase 3, Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of TAK-491 With Valsartan in Chinese Subjects With Essential Hypertension

description: The purpose of this study is to evaluate the antihypertensive effect of azilsartan medoxomil compared with valsartan in Chinese participants with essential hypertension.
DOI: 10.25934/pr00007570
title: A Randomized, Open-label, 2×2 Crossover, Phase I Study to Evaluate the Bioequivalence of Single Oral Dose of TAK-536 Pediatric Formulations and TAK-536 Commercial Tablet in Healthy Adult Male Subjects

description: The purpose of this study is to evaluate the bioequivalence of a single oral dose of 2 different drug forms of TAK-536 pediatric formulation and a single oral dose of TAK-536 commercial tablet in healthy Japanese adult male participants.
DOI: 10.25934/pr00007571
title: A Phase 3, Open-label, Multicenter, Long-term Study to Evaluate the Safety, Efficacy and Pharmacokinetics of TAK-536 in Pediatric Patients 6 to Less Than 16 Years of Age With Hypertension

description: The purpose of this study is to evaluate the safety of administration of azilsartan in pediatric patients aged 6 to less than 16 years with hypertension.
DOI: 10.25934/pr00007572
title: A Phase 1/2, Single-arm, Open-label Study of SGN-35 in Japanese Patients with Relapsed/Refractory CD30-positive Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00007413
title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of TVP-1012 at 1 mg in Early Parkinson's Disease Patients Not Treated With Levodopa

description: The purpose of this study is to evaluate the efficacy and safety of TVP-1012 (1 mg/day) administered to Japanese patients with early Parkinson's disease.
DOI: 10.25934/00007410
title: A Multicenter, Open-label, Long-term, Extension, Phase 3 Study to Evaluate the Safety and Efficacy of TVP-1012 at 1 mg in Early Parkinson's Disease Patients Not Treated With Levodopa

description: The purpose of this study is to evaluate the long-term safety of TVP-1012 (1 mg/day) in Japanese participants with early Parkinson's disease.
DOI: 10.25934/00007412
title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2/3 Study to Evaluate the Efficacy and Safety of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Patients With Wearing Off

description: The purpose of this study is to evaluate the efficacy and safety of TVP-1012 (0.5 mg or 1 mg/day) as an add-on to levodopa in Japanese participants with Parkinson's disease with wearing-off phenomenon.
DOI: 10.25934/00007411
title: A Multicenter, Open-label, Long-term, Phase 3 Study to Evaluate the Safety and Efficacy of TVP-1012 at 1 mg in Levodopa Treated Parkinson's Disease Patients

description: The purpose of this study is to evaluate long-term safety of TVP-1012 (1 mg/day) with levodopa in Japanese participants with Parkinson's disease.
DOI: 10.25934/00007365
title: A Randomized Double-Blind Phase 4 Study to Evaluate the Safety and Proportion of Subjects With Fistula Healing in 2 Dose Regimens of Entyvio (Vedolizumab IV) in the Treatment of Fistulizing Crohn's Disease (ENTERPRISE)

description: The purpose of this study is to evaluate the percentage of participants with perianal fistula healing at Week 30 in 2 different dose regimens of vedolizumab intravenous (IV) 300 milligram (mg) in participants with fistulizing Crohn's disease (CD).
DOI: 10.25934/00007366
title: A Phase 1, Open-Label, Randomized, Parallel Group Study to Compare the Pharmacokinetics of Single Subcutaneous Injections of Vedolizumab Administered in Prefilled Syringe Versus Prefilled Syringe in Needle Safety Device in Healthy Subjects

description: The purpose of this study is to compare the PK of single dose of vedolizumab SC 108 milligram (mg) administered as PFS vs investigational device.
DOI: 10.25934/00007367
title: A Phase 1, Open-Label, Randomized, Parallel Group Pilot Study to Compare the Pharmacokinetics of Single Subcutaneous Injections of Vedolizumab Administered in Prefilled Syringe Versus Prefilled Syringe in Needle Safety Device in Healthy Subjects

description: The purpose of this study is to compare the PK of single dose of vedolizumab SC 108 milligram (mg) administered as PFS vs investigational device.
DOI: 10.25934/00007368
title: A Phase 1, Open-Label, Randomized, Parallel Group Pilot Study to Compare the Pharmacokinetics of Single Subcutaneous Injections of Vedolizumab Administered in Prefilled Syringe Versus Prefilled Syringe in Autoinjector in Healthy Subjects

description: The purpose of this study is to compare PK of single dose of vedolizumab SC 108 milligram (mg) administered as PFS vs investigational device.
DOI: 10.25934/00007069
title: An Open-Label, Single-Arm, Multicenter, Prospective, Phase 4, Interventional, Flexible Dose Study to Evaluate the Effectiveness of Vortioxetine on Goal Achievement After a Change in Antidepressant Medication for the Treatment of Subjects With Major Depressive Disorder

description: The purpose of this study is to determine the effectiveness of treatment with vortioxetine on participant goal achievement after a change in antidepressant medication for the treatment of major depressive disorder (MDD).
DOI: 10.25934/00007369
title: A Phase 1, Open-Label, Randomized, Parallel Group Study to Compare the Pharmacokinetics of Single Subcutaneous Injections of Vedolizumab Administered in Prefilled Syringe Versus Prefilled Syringe in Autoinjector in Healthy Subjects

description: The purpose of this study is to compare the PK of single dose of Vedolizumab SC 108 milligram (mg) administered as PFS vs investigational device.
DOI: 10.15468/dl.mvjp4u
title: Occurrence Download

description: A dataset containing 463 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Vespidae",
 "Year is 1904",
 "Continent is Europe",
 "HasCoordinate is true"
 ]
}

 The dataset includes 463 records from 7 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0037640-250920141307145/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.5281/zenodo.17246764
title: Data from Gorniak & Pollonini - Neurophotonics 2026 (Developing an Inclusive Approach to fNIRS Research in Women of Color)

description: Data from the published manuscript: Pollonini, L., Gorniak, S.L. (2026). Developing an Inclusive Approach to fNIRS Research in Women of Color. Neurophotonics. 13(Suppl 1):S13003. PMID: 40950528 

As public sharing of protected health information, such as date of birth, date of diagnosis, dates of treatment, and other private medical history information pertinent to each participant, may violate HIPAA and the Texas Medical Privacy Act, these data are not be shared to protect patient identity.
DOI: 10.5281/zenodo.17246765
title: Data from Gorniak & Pollonini - Neurophotonics 2026 (Developing an Inclusive Approach to fNIRS Research in Women of Color)

description: Data from the published manuscript: Pollonini, L., Gorniak, S.L. (2026). Developing an Inclusive Approach to fNIRS Research in Women of Color. Neurophotonics. 13(Suppl 1):S13003. PMID: 40950528 

As public sharing of protected health information, such as date of birth, date of diagnosis, dates of treatment, and other private medical history information pertinent to each participant, may violate HIPAA and the Texas Medical Privacy Act, these data are not be shared to protect patient identity.
DOI: 10.26023/r8jn-z3tg-2e0n
title: HIPPO-5 Multiple Enclosure Device for Unfractionated Sampling of Air (MEDUSA) Flask Data. Version 2.0

description: The Multiple Enclosure Device for Unfractionated Sampling of Air (MEDUSA) flask data contains measurements of O2, CO2, Ar/N2 13CO2, and C18O16O. The data were collected by the NCAR GV during HIPPO-5. The data are in NASA Ames format.
DOI: 10.15468/dl.6rjzts
title: Occurrence Download

description: A dataset containing 451 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Pittosporum tobira",
 "Country is United States of America",
 "HasCoordinate is true"
 ]
}

 The dataset includes 451 records from 38 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0037641-250920141307145/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.3srfmn
title: Occurrence Download

description: A dataset containing 393 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is Peru",
 "OccurrenceStatus is Present",
 "TaxonKey is Avicularia"
 ]
}

 The dataset includes 393 records from 7 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0037643-250920141307145/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.13140/2.1.2928.6406
title: Mediterranean J of Educational Studies
DOI: 10.15468/dl.u3jqh3
title: Occurrence Download

description: A dataset containing 123706 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is United States of America",
 "OccurrenceStatus is Present",
 "TaxonKey is Sylvilagus",
 "Year 2017-2025"
 ]
}

 The dataset includes 123706 records from 42 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0037590-250920141307145/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.26747822
title: Additional file 3 of Propionate production by Bacteroidia gut bacteria and its dependence on substrate concentrations differs among species

description: Additional file 3: Table S4. Results of BLASTp searches with 11 Bacteroidia species against amino acid sequences of characterized enzymes of the central carbon and energy metabolism. Table S5. Results of BLASTn searches with two genomes each of the strains B. graminisolvens XDT-1 and B. propionicifaciens SV434 against amino acid sequences of characterized enzymes of the central carbon and energy metabolism.
DOI: 10.6084/m9.figshare.26747855.v1
title: Additional file 1 of Emotion AWARE: an artificial intelligence framework for adaptable, robust, explainable, and multi-granular emotion analysis

description: Supplementary File 1.
DOI: 10.6084/m9.figshare.26748107
title: Additional file 1 of The expression and clinical significance of CFAP65 in colon cancer

description: Supplementary Material 1
DOI: 10.6084/m9.figshare.26741390
title: Additional file 1 of Differences in neutralizing antibody sensitivities and envelope characteristics indicate distinct antigenic properties of Nigerian HIV-1 subtype G and CRF02_AG

description: Supplementary Material 1: Table S1.Panel of 50 subtype G Envs and 18 CRF02_AG Envs from Nigeria. The participants and subtype/CRF for each env clone in the panel are listed at the left of the table. The years in which the samples were collected, the samples source, the amino acid sequence for the tip of the V3 loop and the coreceptor usage (R5 denotes CCR5 usage and X4/R5 denotes dual tropic or use of both CXCR4 and CCR5) are indicated. Bold and italic font indicate PSV for which the Geno2Pheno tool was used to predict coreceptor usage.
DOI: 10.15468/dl.qxhes8
title: Occurrence Download

description: A dataset containing 0 species occurrences available in GBIF matching the query:
{
 "Geometry" : [
 "POLYGON ((149.036504 -34.43986, 149.036504 -34.444351, 149.040996 -34.444351, 149.040996 -34.43986, 149.036504 -34.43986))"
 ]
}

 The dataset includes 0 records from 0 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0071262-240626123714530/datasets/export for details.
DOI: 10.6084/m9.figshare.26741435
title: Additional file 3 of Benchmarking computational variant effect predictors by their ability to infer human traits

description: Additional file 3. The number of variants (by gene) for which each predictor provided scores in the UK Biobank (Table S3) and All of Us (Table S4) cohorts.
DOI: 10.6084/m9.figshare.26748314
title: Additional file 5 of Impact of baseline body composition on prognostic outcomes in urological malignancies treated with immunotherapy: a pooled analysis of 10 retrospective studies

description: Supplementary Material 5
DOI: 10.15468/dl.htxdmz
title: Occurrence Download

description: A dataset containing 0 species occurrences available in GBIF matching the query:
{
 "Geometry" : [
 "POLYGON ((148.542428 -34.442105, 148.542428 -34.444351, 148.544674 -34.444351, 148.544674 -34.442105, 148.542428 -34.442105))"
 ]
}

 The dataset includes 0 records from 0 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0071263-240626123714530/datasets/export for details.
DOI: 10.6084/m9.figshare.26741594.v1
title: Additional file 1 of Liver autotransplantation and atrial reconstruction on a patient with multiorgan alveolar echinococcosis: a case report

description: Supplementary Material 1.
DOI: 10.6084/m9.figshare.26741507
title: Additional file 2 of Heterogeneous pseudobulk simulation enables realistic benchmarking of cell-type deconvolution methods

description: Additional file 2. Supplementary tables S1-S4 referenced in the main text.
DOI: 10.6084/m9.figshare.26739366
title: Additional file 2 of Identification of transposable element families from pangenome polymorphisms

description: Supplementary Material 2.
DOI: 10.6084/m9.figshare.26741444
title: Additional file 1 of Identification of immune-associated biomarkers of diabetes nephropathy tubulointerstitial injury based on machine learning: a bioinformatics multi-chip integrated analysis

description: Supplementary Material 1
DOI: 10.6084/m9.figshare.26748065.v1
title: Additional file 10 of A strategy to detect metabolic changes induced by exposure to chemicals from large sets of condition-specific metabolic models computed with enumeration techniques

description: Supplementary Material 10. S5 Table. DAR subnetwork coverage. This table lists the DAR subnetwork coverage for each identified subnetwork for amiodarone and valproic acid.
DOI: 10.6084/m9.figshare.26748062.v1
title: Additional file 9 of A strategy to detect metabolic changes induced by exposure to chemicals from large sets of condition-specific metabolic models computed with enumeration techniques

description: Supplementary Material 9: S4 Table. Side compounds identifiers. This table lists the sides compounds used in the network analysis stages.
DOI: 10.15468/dl.p78cgv
title: Occurrence Download

description: A dataset containing 195 species occurrences available in GBIF matching the query:
{
 "Geometry" : [
 "POLYGON ((148.834382 -34.428631, 148.834382 -34.437614, 148.84112 -34.437614, 148.84112 -34.444351, 148.850103 -34.444351, 148.850103 -34.446597, 148.85684 -34.446597, 148.85684 -34.43986, 148.843365 -34.43986, 148.843365 -34.437614, 148.845611 -34.437614, 148.845611 -34.435368, 148.84112 -34.435368, 148.84112 -34.433122, 148.836628 -34.433122, 148.836628 -34.428631, 148.834382 -34.428631))"
 ]
}

 The dataset includes 195 records from 2 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0071264-240626123714530/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.26740193
title: Additional file 2 of Construction of a high-density genetic map and QTL localization of body weight and wool production related traits in Alpine Merino sheep based on WGR

description: Supplementary Material 2
DOI: 10.6084/m9.figshare.26740193.v1
title: Additional file 2 of Construction of a high-density genetic map and QTL localization of body weight and wool production related traits in Alpine Merino sheep based on WGR

description: Supplementary Material 2
DOI: 10.57745/boagej
title: Script_Digestion_Article_Final.html

description: :unav
DOI: 10.5281/zenodo.13329848
title: Dataset of the article : Socio-ecological metabolism and rural livelihood conditions: two case studies on forest litter uses in France and Poland (1875-1910)
DOI: 10.5281/zenodo.13329849
title: Dataset of the article : Socio-ecological metabolism and rural livelihood conditions: two case studies on forest litter uses in France and Poland (1875-1910)